MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

NCT07029776 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance
PROCEDURE: melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy

Sponsor

University of Arkansas

Collaborators

[object Object]